dornase alfa

(redirected from Dornase)
Also found in: Medical.

dor·nase al·fa

 (dôr′nās′ ăl′fə, -nāz′)
A genetically engineered enzyme used to hydrolyze the DNA in bronchial mucus, facilitating its expectoration, in the treatment of cystic fibrosis.

[(recombinant human) d(e)o(xy)r(ibo)n(ucle)ase (1) + alteration of alpha.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Sodium chloride 7% was another drug which went on display at the ceremony today and is recommended for use in patients aged six years of age and over with a respiratory condition leading to retained bronchopulmonary secretions and where usual treatment (physiotherapy airway clearance, adequate systemic hydration, dornase alpha for those with CF, carbocisteine where indicated) isn't sufficiently effective.
Currently, the company expects several biosimilars to be in clinical trials: Rituximab biosimilar (JHL1101) to treat rheumatoid arthritis and Non-Hodgkin's Lymphoma; Dornase alfa biosimilar (JHL1922) to manage symptoms of cystic fibrosis; as well as Trastuzumab biosimilar (JHL1188) to treat breast cancer.
Nolan, "Dornase alfa for cystic fibrosis," Cochrane Database of Systematic Reviews, vol.
Due to bleeding risk, decortication was deferred and the patient was instead treated with intrapleural tPA and dornase alpha.
We hypothesize that bronchopleural fistula contributed to treatment failure with intrapleural tPA and dornase. In a cohort of 27 AIDS patients with pneumothorax (PTX), 10 had a bronchopleural fistula [11].
NORDIC BUSINESS REPORT-December 21, 2017-JHL submits clinical trial application with the Dutch Healthcare Authority for proposed clinical trial of Dornase Alfa Biosimilar in the Netherlands
It was further treated with fibrinolytics (tissue plasminogen activator) and dornase alpha since surgery was nonoptional due to multiorgan failure and septic shock.
(4) Thick secretions can be treated directly and enzymatically with nebulized dornase alpha, (4,8) which is also best administered before mechanical clearance therapy.
In contrast to control groups patients from the main group received the inhalation with surfactant emulsion 12 ml per kg, dornase alfa (25 mg, 2 times a day), almitrin (scheme).
Medications included pancreatic enzyme supplements, proton-pump inhibitors, [beta]-agonist, fat-soluble vitamin supplements, dornase alpha, and inhaled tobramycin.
Inhaled dornase alpha (Pulmozyme[R]) targets a specific component of mucus overproduction, but is only approved for patients with cystic fibrosis."